Apr 18, 2024
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Apr 17, 2024
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Mar 05, 2024
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Jan 30, 2024
Immutep Quarterly Activities Report Q2 FY24
Jan 04, 2024
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
